Pulmonx Corp (LUNG) — SEC Filings
Pulmonx Corp (LUNG) — 36 SEC filings. Latest: 8-K (Apr 29, 2026). Includes 14 8-K, 11 SC 13G/A, 5 10-Q.
View Pulmonx Corp on SEC EDGAR
Overview
Pulmonx Corp (LUNG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Oct 27, 2025: Pulmonx Corp. announced on October 21, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Boston Scientific Corporation for $3.1 billion in cash. The transaction is expected to close in the first half of 2026, subject to customary closing conditions, including re
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 31 neutral, 1 mixed. The dominant filing sentiment for Pulmonx Corp is neutral.
Filing Type Overview
Pulmonx Corp (LUNG) has filed 14 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 11 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of LUNG's 24 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $45.9M |
| Net Income | -$25.3M |
| Cash Position | $189.0M |
Key Executives
- Glendon E. French
- Tiffany Sullivan
- Dr. Michael J. Zwick
- Flynn James E
- Abigail P. Johnson
Industry Context
Pulmonx operates in the medical device sector, specifically focusing on treatments for severe lung disease. The industry is characterized by significant R&D investment, regulatory hurdles, and a need for clinical validation. Competition often comes from established players with broader product portfolios and from emerging technologies.
Top Tags
financial-condition (5) · institutional-ownership (5) · medical-devices (4) · 10-Q (4) · operations-update (3) · corporate-governance (3) · financials (3) · Pulmonx (3) · amendment (3) · Medical Devices (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Acquisition Price | $3.1B | Total cash consideration for Pulmonx Corp. |
| Q2 2025 Revenue | $45.9M | Increased 21% from $37.9M in Q2 2024 |
| Q2 2025 Net Loss | -$25.3M | Widened from -$20.1M in Q2 2024 |
| Accumulated Deficit | $459.0M | Increased from $433.7M at March 31, 2025 |
| Cash and Cash Equivalents | $189.0M | Decreased from $210.0M at December 31, 2024 |
| Revenue Growth | 21% | Year-over-year increase in Q2 2025 revenue |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Filing Date | 2025-05-02 | The date the 10-Q was officially submitted to the SEC. |
| Previous Year End Date | 2024-12-31 | Provides a comparison point for financial changes. |
| Annual Meeting Date | 20250522 | Date of the shareholder meeting where proposals will be voted on. |
| Year-to-Date Period | 2024-01-01 to 2024-09-30 | Covers the first nine months of the fiscal year 2024. |
| Prior Year-to-Date Period | 2023-01-01 to 2023-09-30 | Covers the first nine months of the fiscal year 2023 for comparison. |
| Period End Date | 2024-03-31 | Quarterly report period |
| Fiscal Year End | 1231 | Annual fiscal year end date |
| Meeting Time | 8:00 a.m. Pacific Daylight Time | Time of the 2024 Annual Meeting of Stockholders |
Forward-Looking Statements
- {"claim":"Pulmonx Corporation's stock price may experience downward pressure due to the reduced institutional ownership.","entity":"Pulmonx Corporation","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in Pulmonx following Deerfield's reduced stake.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"PRIMECAP Management Company will maintain a significant stake in Pulmonx Corp.","entity":"PRIMECAP Management Company","targetDate":"December 31, 2024","confidence":"medium"}
- {"claim":"FMR LLC will maintain its significant stake in Pulmonx Corp for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Pulmonx Corp (LUNG)?
Pulmonx Corp has 36 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 11 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LUNG filings?
Across 36 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 31 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Pulmonx Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pulmonx Corp (LUNG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pulmonx Corp?
Key financial highlights from Pulmonx Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LUNG?
The investment thesis for LUNG includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pulmonx Corp?
Key executives identified across Pulmonx Corp's filings include Glendon E. French, Tiffany Sullivan, Dr. Michael J. Zwick, Flynn James E, Abigail P. Johnson.
What are the main risk factors for Pulmonx Corp stock?
Of LUNG's 24 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Pulmonx Corp?
Recent forward-looking statements from Pulmonx Corp include guidance on {"claim":"Pulmonx Corporation's stock price may experience downward pressure due to the reduced institutional ownership. and 3 other predictions.